Circulating miR-92b and miR-375 for monitoring the chemoresistance and prognosis of small cell lung cancer
Authors:
Open Access
- 29 July 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Abstract
MiRNAs have been reported to be stably detectable in plasma and to function as potent biomarkers in multiple cancers. The study aimed to evaluate the expression of candidate circulating miRNAs in patients with small cell lung cancer (SCLC) to identify potential noninvasive biomarkers. The expression of five miRNAs (miR-92b, miR-146a, miR-375, miR-1224, and miR-1246) was significantly upregulated in plasma after chemoresistance induction. Receiver operating characteristic curve (ROC) analysis showed that the area under the curve (AUC) values of miR-92b and miR-375 were 0.766 and 0.791, respectively. The data demonstrated that among the five miRNAs assessed, these two miRNAs had better diagnostic accuracy for monitoring drug resistance. In addition, miR-92b and miR-375 levels were decreased after effective chemotherapy. Furthermore, Kaplan–Meier survival analysis confirmed that high expression of miR-92b and miR-375 was closely related to shorter progression-free survival (PFS) in SCLC patients. In conclusion, these findings indicate that circulating miR-92b and miR-375 might be ideal noninvasive biomarkers for monitoring drug resistance during chemotherapy and evaluating the prognosis of patients with SCLC.Keywords
Funding Information
- Fundamental Research Funds for the Central University (WK9110000025)
- National Cancer Center Climbing Fundation (NCC201812B036)
- National Natural Science Foundation of China (81672647, 81972191)
- Science and Technology Major Project of Anhui Province (18030801140)
- Key Program of 13th five-year plan of CASHIPS (KP-2017-26)
This publication has 23 references indexed in Scilit:
- Annual report to the nation on the status of cancer, part I: National cancer statisticsCancer, 2020
- Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrenceAmerican Journal of Transplantation, 2019
- Regulation of microRNA biogenesis and its crosstalk with other cellular pathwaysNature Reviews Molecular Cell Biology, 2018
- MiR-375 is epigenetically downregulated due to promoter methylation and modulates multi-drug resistance in breast cancer cells via targeting YBX1.2016
- miR-1290 is a potential prognostic biomarker in non-small cell lung cancer2015
- The Regulatory Role of MicroRNAs in EMT and CancerJournal of Oncology, 2015
- Claudin-1 is a novel target of miR-375 in non-small-cell lung cancerLung Cancer, 2014
- MicroRNAs in CancerAnnual Review of Pathology: Mechanisms of Disease, 2014
- Trends in incidence of small cell lung cancer and all lung cancerLung Cancer, 2012
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences, 2008